Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy

W. C. Nichols, L. K. Kvols, J. N. Ingle, J. H. Edmonson, D. L. Ahmann, J. Rubin, M. J. O'Connell

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

The purpose of this phase II clinical trial was to evaluate the effectiveness of triazinate and pyrazofurin in the treatment of advanced breast cancer. Although an occasional patient experienced stability of disease, neither agent, as employed in this study, was able to produce an objective antitumor effect in this group of patients with previous chemotherapeutic exposure. At the dosages used in this study, neither agent can be recommended for further treatment of advanced breast cancer.

Original languageEnglish (US)
Pages (from-to)837-839
Number of pages3
JournalCancer Treatment Reports
Volume62
Issue number5
StatePublished - Dec 1 1978

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy'. Together they form a unique fingerprint.

  • Cite this

    Nichols, W. C., Kvols, L. K., Ingle, J. N., Edmonson, J. H., Ahmann, D. L., Rubin, J., & O'Connell, M. J. (1978). Phase II study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy. Cancer Treatment Reports, 62(5), 837-839.